Overview
rs717620 is a genetic variant associated with Dubin-johnson syndrome and Spondyloepiphyseal dysplasia.
This variant is located on chromosome 10. The variations at position 99782821 are the genetic letters C/C, T/T, C/T
Since humans have each twice (one from each parent), these letter-variations occur on both chromosomes. People can have the same or different letters on both chromosomes. Every person's individual variation combination is referred to as genotype. For variant rs717620 there are 3 currently known genotypes : C/C, T/T or C/T
Short Overview
Variant Location
rs717620 is located on gene in chromsome 10. Use the genome browser to explore the location of rs717620 and its genetic neighbourhood.
Conditions & Traits
rs717620 affects the following conditions and traits:
Pathogenicity
rs717620 affects the following conditions:
Pharmacogenetics
rs717620 affects the following drugs:
Genome Browser
This interactive browser visualizes what no human can see with the naked eye - our DNA. From a down to a specific position on a . The position you are looking at here is the exact location of variant rs. Explore more variants and their effects on the body by browsing left and right along the DNA strand.
Did you know genetic variants affect drugs?
Mutations are changes in genes and genetic variations are differences in the DNA among people. Variants are tiny changes in just one piece of the DNA while haplotypes are groups of these changes that usually come together.
Conditions & Traits of rs717620
The different genotypes of variant rs717620 can affect the likelyhood of developing certain traits or conditions. Current research shows that 2 conditions and 0 traits are associated with rs717620. The following table shows the relationship between genotypes and conditions and traits.
Classification of Variants
Variants can be classified either based on scientific studies or clinical tests. Scientific studies classifications aim to uncover the function of genetic variants and their role in conditions, traits, and evolution. Variants are categorized according to their functional effect, such as loss-of-function (reduced gene activity), gain-of-function (increased gene activity), neutral (no significant impact) or evolutionary conservation. This classification uses experimental data, population studies, and computational analyses to understand the long-term effects of variants. Clinical testing classifications, however, focus on the immediate health impact on the human body, distinguishing five categories from disease causing (harmful) to no effect (not harmful). This classification relies on a mix of family history, lab tests, and computer predictions, aiming to assist doctors in making medical decisions.
Conditions
2Genotype
C
C
Level of evidence
Sources
No effect
Unisex
1 Sources
Participants: 0
The genotype with the letters C/C is thought to have no effect on your disease risk. Carriers of this genetic result are usually not at risk of developing the disease.
Genotype
T
T
Level of evidence
Sources
No effect
Unisex
1 Sources
Participants: 0
The genotype with the letters T/T is thought to have no effect on your disease risk. Carriers of this genetic result are usually not at risk of developing the disease.
Genotype
C
T
Level of evidence
Sources
No effect
Unisex
1 Sources
Participants: 0
The genotype with the letters C/T is thought to have no effect on your disease risk. Carriers of this genetic result are usually not at risk of developing the disease.
Pharmacogenetics
The genetic variant rs717620 impacts how certain medications work in the body. This difference may cause some of us to require different dosage amounts to achieve the desired effects, while others might experience more apparent side-effects. As a result, healthcare providers may need to adjust prescriptions for those individuals with rs717620. Ultimately, understanding our genetic makeup helps improve the overall effectiveness and usability of medications. Tailoring treatments based on genetics ensures a safer, more personalized healthcare experience.
Genotype
Level of evidence
Impacts
Summary
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype C/C have increased Drug Effect to CISPLATIN.
more info
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype C/T have decreased Drug Effect to CISPLATIN.
more info
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype T/T have decreased Drug Effect to CISPLATIN.
more info
Legend:
Increased
Decreased
No known effect
Genotype
Level of evidence
Impacts
Summary
Breakdown
Drug Effect
Side Effects
Dosage
No summary available.
more info
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype C/T have increased Breakdown to CYCLOSPORINE.
more info
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype T/T have increased Breakdown to CYCLOSPORINE.
more info
Legend:
Increased
Decreased
No known effect
Genotype
Level of evidence
Impacts
Summary
Breakdown
Drug Effect
Side Effects
Dosage
No summary available.
more info
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype C/T have increased Side Effects to DEFERASIROX.
more info
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype T/T have increased Side Effects to DEFERASIROX.
more info
Legend:
Increased
Decreased
No known effect
Genotype
Impacts
Breakdown
Drug Effect
Side Effects
Dosage
Summary
Individuals with the genotype C/C have increased Drug Effect to CISPLATIN.
Level of evidence
More info
Genotype
Impacts
Breakdown
Drug Effect
Side Effects
Dosage
Summary
Individuals with the genotype C/T have decreased Drug Effect to CISPLATIN.
Level of evidence
More info
Genotype
Impacts
Breakdown
Drug Effect
Side Effects
Dosage
Summary
Individuals with the genotype T/T have decreased Drug Effect to CISPLATIN.
Level of evidence
More info
Legend:
Increased
Decreased
No known effect
Genotype
Impacts
Breakdown
Drug Effect
Side Effects
Dosage
Summary
No summary available.
Level of evidence
More info
Genotype
Impacts
Breakdown
Drug Effect
Side Effects
Dosage
Summary
Individuals with the genotype C/T have increased Breakdown to CYCLOSPORINE.
Level of evidence
More info
Genotype
Impacts
Breakdown
Drug Effect
Side Effects
Dosage
Summary
Individuals with the genotype T/T have increased Breakdown to CYCLOSPORINE.
Level of evidence
More info
Legend:
Increased
Decreased
No known effect
Genotype
Impacts
Breakdown
Drug Effect
Side Effects
Dosage
Summary
No summary available.
Level of evidence
More info
Genotype
Impacts
Breakdown
Drug Effect
Side Effects
Dosage
Summary
Individuals with the genotype C/T have increased Side Effects to DEFERASIROX.
Level of evidence
More info
Genotype
Impacts
Breakdown
Drug Effect
Side Effects
Dosage
Summary
Individuals with the genotype T/T have increased Side Effects to DEFERASIROX.
Level of evidence
More info
Legend:
Increased
Decreased
No known effect
Drugs related to rs717620
All drugs that are linked to rs717620 are listed here.
Studies and Sources
All of the resources below examine variant rs717620
Romy Tilen, Paolo Paioni, Aljoscha N. Goetschi, Roland Goers, Isabell Seibert, Daniel Müller, Julia A. Bielicki, Christoph Berger, Stefanie D. Krämer, Henriette E. Meyer zu Schwabedissen
Beata Franczyk, Jacek Rysz, Jarosław Miłoński, Tomasz Konecki, Magdalena Rysz-Górzyńska, Anna Gluba-Brzózka
Ludmila Vodickova, Josef Horak, Pavel Vodicka